FINANCINGS
Alkermes plc netted $248.4 million in a new share offering from two Invesco Perpetual funds.
Applied Genetic Technologies filed for a $70 million IPO, with plans to list on Nasdaq under the symbol “AGTC.”
Atara Biotherapeutics Inc.’s second closing of its Series B financing brought the total raised to $52 million.
Bio-Path Holdings Inc. is raising about $10 million in a registered direct offering at a price of $3 per unit.
Biota Pharmaceuticals Inc. priced a public offering for an aggregate amount of $25 million.
Concert Pharmaceuticals Inc. filed for an IPO to raise $74.75 million.
Glycomimetics Inc. successfully completed its IPO, pricing 8.05 million shares at $8 per share.
Intra-Cellular Therapies Inc. filed for a $115 million IPO.
Juno Therapeutics Inc. expanded its Series A round with the total now raised exceeding $145 million.
Microlin Bio filed to raise up to $25 million in an IPO.
Pronai Therapeutics Inc. closed a Series C preferred financing round, raising more than $12 million.
Rexahn Pharmaceuticals Inc. is raising $20 million in a registered direct offering.
DEALS
Agenus Inc. entered a definitive agreement to acquire 4-Antibody AG.
Alexion Pharmaceuticals Inc. purchased 10 product options from Moderna Therapeutics Inc. relating to its mRNA technology platform, to develop and commercialize rare disease treatments.
Alnylam Pharmaceuticals Inc. said Genzyme bought $700 million worth of its shares at $80 each.
Alnylam Pharmaceuticals Inc. paid $175 million to Merck & Co. Inc. to acquire Sirna Therapeutics Inc.
Amgen Inc. and Illumina Inc. are developing a companion diagnostic for Vectibix.
Jazz Pharmaceuticals plc has licensed a narcolepsy drug from Aerial Biopharma LLC.
Nantbioscience, a subsidiary of Nantworks LLC, is collaborating with Celgene Corp. to develop cancer drugs.
Novartis AG has handed back rights to Cell Therapeutics Inc. to two cancer compounds.
Novasaid AB and Cadila Pharmaceuticals Ltd. are partnering to develop treatments for inflammation and pain.
Nuevolution A/S entered a licensing agreement giving Novartis AG use of its Chemetics technology.
Selvita SA extended its chemistry research collaboration with Chiesi Farmaceutici SpA.
Regeneron Pharmaceuticals Inc. signed a new deal for a combination therapy in wet AMD with Bayer AG.
Shire plc extended the expiration of its tender offer for all outstanding shares of Viropharma Inc. to Jan. 23.
Triphase Accelerator Corp. provided Celgene Corp. rights of first refusal on their first three oncology products.
. . . AND MORE
Check out BioWorld Today’s extensive coverage of the 32nd annual J.P. Morgan Healthcare Conference held last week.
Lexicon Pharmaceuticals Inc. reported a 45 percent work force reduction.
Moderna Therapeutics Inc. launched Onkaido Therapeutics, a new venture developing mRNA-based oncology treatments.
The Medicines Co. said the FDA designated Carbavance as a Qualified Infectious Disease Product.